Tesamorelin vs Sermorelin vs Ipamorelin

Tesamorelin is a modified GHRH analog with 44 amino acids and a trans-3-hexenoic acid group at the N-terminus. It is the active ingredient in Egrifta SV, FDA-approved in 2010 for visceral fat reduction in HIV-associated lipodystrophy. Theratechnologies manufactures the brand product.

The half-life is 26-38 minutes. Daily subcutaneous injection at 2 mg produces a physiological GH pulse that clears within hours. In Phase III trials, 69% of subjects achieved the FDA responder threshold of greater than 8% visceral adipose tissue reduction (Falutz et al., NEJM, 2007).

Tesamorelin also reduced liver fat and improved triglyceride profiles in the Stanley 2014 JAMA study, making it the most metabolically well-characterized GHRH analog available (Stanley et al., JAMA, 2014). For dosing details, see our tesamorelin dosage for fat loss guide.

Sermorelin is the first 29 amino acids of endogenous GHRH(1-44), representing the shortest fragment that retains full biological activity at the GHRH receptor. It was previously FDA-approved under the brand name Geref for diagnosis and treatment of pediatric growth hormone deficiency.

Geref was discontinued by its manufacturer due to production challenges, not safety concerns. Sermorelin remains available through compounding pharmacies with a valid prescription. Its half-life of 10-20 minutes is the shortest of the three, producing the most transient and physiologically natural GH pulse.

Walker et al. (2006) demonstrated that sermorelin preserves the pituitary neuroendocrine axis and stimulates endogenous hGH mRNA expression, suggesting it supports rather than suppresses the body's own GH production capacity (Walker et al., Horm Res, 2006). Standard dosing is 200-500 mcg subcutaneously before bed. For safety data, see our is sermorelin safe guide. For body composition effects, see sermorelin for fat loss.

Ipamorelin is a synthetic pentapeptide (5 amino acids: Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts on the ghrelin receptor (GHS-R1a), not the GHRH receptor. This makes it mechanistically distinct from both tesamorelin and sermorelin, and it is the key reason ipamorelin stacks synergistically with either one.

The Raun 1998 study established ipamorelin as the first selective GH secretagogue. At doses up to 200 times the effective threshold, cortisol, ACTH, prolactin, FSH, LH, and TSH remained unchanged (Raun et al., Endocrinology, 1998). No other GH-releasing compound has matched this selectivity profile.

The half-life is approximately 2 hours, with a GH peak at about 40 minutes post-injection and dose-proportional pharmacokinetics (Johansen et al., Eur J Clin Pharmacol, 1999). Standard dosing is 100-300 mcg subcutaneously, most commonly paired with CJC-1295 for GHRH-GHRP synergy. For the comparison with MK-677 (the oral ghrelin mimetic), see our MK-677 vs ipamorelin guide.

The most important distinction in this three-way comparison is the receptor pathway. Tesamorelin and sermorelin share one pathway. Ipamorelin uses a completely different one.

Tesamorelin and sermorelin are both GHRH receptor agonists. They bind the GHRH receptor on pituitary somatotroph cells, triggering GH synthesis and release. Because they target the same receptor, stacking them together is pharmacologically redundant: the receptor can only respond so many times per hour regardless of how many agonists are competing for it.

Ipamorelin targets the ghrelin receptor (GHS-R1a), which triggers GH release through a separate signaling cascade. When you pair a GHRH analog with ipamorelin, you activate two complementary pathways simultaneously. The GHRH analog stimulates GH production and synthesis. Ipamorelin prompts GH secretion. The result is a GH pulse larger than either compound achieves alone.

For stacking guidance, see our peptide stacking guide.

The three peptides sit at different rungs of the clinical evidence ladder. This matters fundamentally for risk assessment and realistic expectations.

For visceral fat reduction, tesamorelin has no competition in this group.

Sermorelin and ipamorelin both elevate GH, which promotes lipolysis. Practitioners and users report body composition improvements on both. These reports are consistent with GH physiology but are not the same as CT-scan-measured outcomes from controlled trials.

For targeted fat loss with documented results, tesamorelin is the evidence-based choice. For the tesamorelin vs CJC-1295 comparison on fat loss, see our tesamorelin vs CJC-1295 guide. For broader context, see best peptides for weight loss.

GH secretion peaks during deep sleep, and all three peptides can enhance this natural rhythm when dosed in the evening.

Sermorelin's 10-20-minute half-life produces a sharp, brief GH pulse that most closely resembles the body's own bedtime secretion pattern. Injecting 200-500 mcg before bed amplifies the natural sleep-associated GH surge without prolonged stimulation. Users consistently report deeper sleep and vivid dreams within the first 1-2 weeks.

Ipamorelin's 2-hour half-life provides a slightly longer GH pulse, still well within the physiological window. Evening injection before bed is the standard protocol. The GH pulse aligns with early deep sleep and clears before morning.

Tesamorelin has no dedicated sleep studies. Its 26-38-minute half-life suggests it could improve sleep through GH-mediated mechanisms, but specific sleep architecture data has not been collected.

For the peptide with dedicated sleep clinical data, see our MK-677 vs ipamorelin comparison (MK-677 has a dedicated sleep RCT). For the broader sleep peptide overview, see peptides for sleep.

For long-term use, pituitary preservation is the key variable. You want a compound that supports your body's GH machinery rather than overriding it.

Sermorelin scores highest on this criterion. Walker 2006 showed sermorelin stimulates endogenous hGH mRNA expression, meaning it promotes the pituitary's own production capacity (Walker et al., 2006). Its short half-life and natural pulsatile pattern minimize desensitization risk. Many longevity physicians favor sermorelin for this reason.

Ipamorelin acts on a different receptor entirely, so it does not desensitize the GHRH pathway. Pairing ipamorelin with a GHRH analog may support pituitary function by providing dual-pathway stimulation without overloading either receptor.

Tesamorelin's potency makes it effective for targeted goals but less ideal for indefinite use. Daily dosing at 2 mg represents a stronger pharmacological stimulus than sermorelin's more moderate approach.

For muscle recovery and body composition in the context of training, the ipamorelin plus CJC-1295 stack is the most widely used clinical protocol.

Ipamorelin's selectivity means no cortisol elevation. Cortisol is catabolic; any GH secretagogue that elevates cortisol post-training counteracts the anabolic GH signal. GHRP-6 and GHRP-2 both raise cortisol. Ipamorelin does not, at any tested dose.

When paired with CJC-1295 (no DAC), the combination delivers GH pulses through two pathways 2-3 times daily, timed around training and sleep. This protocol produces the highest acute GH spikes of any non-HGH secretagogue approach. For the full stack breakdown, see CJC-1295/ipamorelin benefits.

Tesamorelin's potency makes it effective for recomposition, particularly reducing stubborn visceral fat. Sermorelin works as a gentler starting point suited for beginners or those prioritizing general recovery over maximum GH output. For training-focused context, see peptides for bodybuilding and peptides for muscle growth.

All three peptides are well tolerated at standard doses. The profiles overlap but have meaningful differences.

Ipamorelin's zero cortisol and zero prolactin profile at any dose is unique among all GH secretagogues, including sermorelin and tesamorelin. Sermorelin has the mildest overall side effect profile. Tesamorelin has the most comprehensive safety data from Phase III trials with 52-week follow-up.

All three are better tolerated than exogenous HGH, which causes higher rates of water retention, carpal tunnel syndrome, insulin resistance, and joint pain. For ipamorelin-specific side effect management, see our CJC-1295/ipamorelin side effects guide. For sermorelin safety, see is sermorelin safe.

Pricing varies by source, formulation, and whether you use brand or compounded products.

Sermorelin is the most budget-friendly option, requiring no combination compound at standard dosing. Ipamorelin becomes more expensive when paired with CJC-1295, the standard protocol in clinical practice. Tesamorelin at compounded prices is competitive with both alternatives, but brand Egrifta SV is prohibitive for non-HIV patients without insurance coverage.

For sourcing information, see where to buy sermorelin. For reconstitution, use our peptide reconstitution calculator.

Stacking GH peptides requires understanding which combinations are synergistic and which are redundant.

The rule is simple: one GHRH analog plus one GHRP. Never two GHRH analogs together. The GHRH analog (tesamorelin, sermorelin, or CJC-1295) stimulates GH synthesis. The GHRP (ipamorelin) stimulates GH release through the ghrelin receptor. Together they create a GH pulse larger than either alone.

For the complete stacking guide, see peptide stacking guide.

This matrix consolidates the comparison into actionable guidance based on your primary goal.

No single peptide wins every category. For the CJC-1295 comparison within the GHRH class, see CJC-1295 vs sermorelin. For the tesamorelin vs CJC-1295 head-to-head, see tesamorelin vs CJC-1295.

All three compounds stimulate GH release and elevate IGF-1. Shared precautions apply across the entire class.

Do not use any GH-stimulating peptide with active cancer or a history of hormone-sensitive cancers (prostate, breast, colorectal) without oncologist clearance. Elevated IGF-1 may theoretically promote tumor growth. Monitor IGF-1 levels during use to ensure they remain within the reference range (normal adult: 80-350 ng/mL).

Tesamorelin is Category X in pregnancy and contraindicated in active malignancy per FDA labeling. CJC-1295 and sermorelin lack formal contraindication labeling since they are not FDA-approved, but the same biological precautions apply.

Monitor fasting glucose periodically. GH is a counter-regulatory hormone to insulin. Report persistent edema, joint pain that limits function, or headaches not resolving with hydration to your prescribing physician. For a comprehensive safety overview covering all peptide classes, see our peptide safety guide.